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Abstract
Purpose Pulmonary vein isolation (PVI) using cryoballoon (CB) ablation is associated with an increased radiation exposure
compared with radiofrequency ablation. Previous studies showed that radiation exposure in CB PVI can be reduced by optimiz-
ing the fluoroscopy protocol without comprising acute efficacy and safety. We evaluated the mid-term outcome of a modified
fluoroscopy protocol in patients undergoing CB PVI.
Methods The study population comprised 90 consecutive patients who underwent second-generation CB-based PVI. The first 46
patients underwent CB PVI with conventional fluoroscopy settings (group A, historic control group). In the following 44 patients
(group B), a modified fluoroscopy protocol was applied consisting of (1) visualization of degree of PV occlusion only by
fluoroscopy (no cine runs); (2) increased radiation awareness. Primary endpoints were the total dose area product (DAP),
fluoroscopy time, and freedom from documented recurrence of atrial fibrillation (AF) after a single procedure.
Results Group B had a lower median DAP (1393 cGycm2 vs. 3232 cGycm2, P < 0.001) and median fluoroscopy time (20 min vs.
24 min, P < 0.001) as compared with group A. The 1-year freedom from documented recurrence of AF after a single procedure
was similar among groups (74% in group A vs. 77% in group B, P = 0.71). There were no significant differences between both
groups for the secondary endpoints, including procedure duration, proportion of patients with complete electrical isolation, and
complications.
Conclusion Using a modified fluoroscopy protocol and increased radiation awareness, radiation exposure can be significantly
reduced in CB PVI with a similar 1-year clinical outcome.
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1 Introduction
Pulmonary vein isolation (PVI) is the cornerstone of invasive
treatment of symptomatic drug-refractory atrial fibrillation
(AF). Currently, the two most frequently used ablation tech-
niques for PVI are radiofrequency (RF) ablation followed by
cryoballoon (CB) ablation. With RF ablation, continuous cir-
cumferential lesions are created around the pulmonary veins
(PV) usually by point-by-point ablation. CB ablation offers a
simpler and less operator-dependent means of achieving PVI
by producing a large circular ablation zone. The landmark
FIRE AND ICE trial and a recent meta-analysis showed that
CB PVI was noninferior to RF ablation with respect to effica-
cy and safety [1, 2]. The CIRCA-DOSE trial reconfirmed the
noninferiority of second-generation CB PVI when compared
with contact-force-guided RF ablation [3]. Besides the less
operator dependency, main advantages of CB ablation are
the shorter procedure time and shorter left atrial (LA) dwell
time [1]. The drawbacks of CB ablation are the increased risk
of phrenic nerve palsy and increased radiation exposure in
comparison to RF ablation [4]. CB PVI requires more exten-
sive fluoroscopic guidance in comparison to RF ablation
where catheter guidance can be achieved with 3D mapping.
There is general consensus that radiation exposure should be
kept as low as possible, not only for patients but also for
catheterization laboratory staff [5]. Previous studies showed
that radiation exposure in second-generation CB procedures
can be reduced by optimizing the fluoroscopy protocol
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without compromising acute efficacy and safety [6, 7]. The
aim of the present study is to evaluate the acute and mid-term
outcome of a modified fluoroscopy protocol and increased




The study population comprised consecutive patients who
underwent their PVI using CB ablation from August 2016
to April 2018 in the Erasmus MC. In our institution, pa-
tients with AF are eligible for PVI using CB ablation
when their PV anatomy is suitable based on their CT scan.
Patients with a common ostium or a large PV (> 24 mm)
were cons idered not su i tab le for CB abla t ion .
Furthermore, patients requiring substrate ablation and/or
a redo PVI were planned for RF ablation. The study pop-
ulation consisted of a historic control group (group A)
using conventional fluoroscopy settings and an interven-
tion group (group B) who had PVI using a modified fluo-
roscopy protocol (start date June 2017). The study was
approved by the local Ethics Committee.
2.2 Periprocedural management
All patients received oral anticoagulation for at least
4 weeks prior to ablation. Patients using vitamin K antag-
onist (VKA) underwent the procedure using uninterrupted
anticoagulation with a target international normalized ra-
tio (INR) between 2.0 and 3.0. Patients using non-
vitamin-K oral anticoagulants (NOAC) skipped their dose
on the morning of the procedure as previously described
[8]. To exclude LA thrombi, all patients underwent trans-
esophageal echocardiogram within 24 h of the procedure.
After the procedure, patients using NOAC restarted their
oral anticoagulation or low-molecular weight heparin 2 h
after the procedure. The following day, an echocardio-
gram was performed to rule out pericardial effusion be-
fore discharge.
2.3 Ablation procedure
In general, CB PVI was performed using conscious seda-
tion. Based on patient preferences, procedures could be
performed under general anesthesia. Vascular access was
usually gained through the right femoral vein using an 8F
and 10F sheath. A steerable decapolar catheter (Inquiry,
Abbott, Lake Bluff, IL) was positioned in either the right
ventricle for bradycardia pacing during freezing of the left
PVs or in the vena cava superior for right phrenic nerve
stimulation during freezing of the right PVs. Transseptal
puncture was performed under fluoroscopic and intracar-
diac echocardiographic (ICE) guidance with the use of a
SL1 transseptal sheath (Abbott, Lake Bluff, IL) and RF
transseptal needle (Baylis Medical, Montreal, Canada).
Heparin was given to maintain an activated clotting time
of > 275 s, which was measured every 30 min. The
transseptal sheath was exchanged over a guidewire for a
12F (outer diameter 15F) steerable transseptal sheath
(FlexCath, Medtronic, Minneapolis, MN) through which
a 28-mm CB (Arctic Front Advance, Medtronic,
Minneapolis, MN) was advanced into the LA. No selec-
tive PV angiography was performed before balloon place-
ment. A 20 mm spiral multipolar mapping catheter
(Achieve, Medtronic, Minneapolis, MN) was used for
guiding the CB to the target PV and real-time measure-
ments of PV potentials during cryoablation. The degree of
PV occlusion was measured by contrast injection through
the central lumen of the inflated CB. The freezing time
was depended on the time-to-isolation (TTI). A freezing
cycle duration was set to 180 s when the TTI was < 60 s;
otherwise, the freezing cycle duration was increased to
240 s. No additional bonus freeze cycle was applied after
achieving PVI. If the PV was not isolated, additional
freeze applications were performed with different align-
ment of the CB with respect to the target PV. If complete
PVI could not be achieved, we did not switch to a RF
catheter for a touch-up ablation. During CB ablation of
the right PVs, the phrenic nerve function was monitored
during pacing of the right phrenic nerve and manual pal-
pation of the abdomen for diaphragmatic contractions.
The freeze cycle was prematurely stopped after loss of
diaphragmatic contractions during right PV ablation or
when the cryoballoon temperature were below − 60 °C
(probably too distal ablation site). Confirmation of dura-
ble PVI was performed 20 min after ablation of the cor-
responding PV.
2.4 Fluoroscopy settings
Both groups underwent CB ablation using the same angiocar-
diography system (Allura FD20, Philips, the Netherlands) by
a limited number of operators (REB, MF, SCY). The fluoros-
copy frame rate in both groups was set to 7.5 pulses per sec-
ond. During fluoroscopy, spectral filters containing 0.9 mm
copper and 1.0 mm aluminum were used; cine runs were per-
formed with filters containing 0.1 mm copper and 1.0 mm
aluminum. In group A (conventional group), the degree of
PV occlusion prior to each freeze cycle was filmed (cine
run). In group B (intervention group), the following modifica-
tions were made: (1) degree of PV occlusion prior to each
freeze cycle was only visualized by fluoroscopy and stored
with the “store fluoroscopy” function (no cine run); (2)
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increased radiation awareness (e.g., optimal collimation, min-
imizing distance between patient and detector, limiting
fluoroscopy) (Fig. 1).
2.5 Follow-up
After the ablation procedure, outpatient clinic visits were rou-
tinely scheduled at 3, 6, and 12 months. These visits included
a 12-lead electrocardiogram (ECG) and ambulatory 7-day
Holter monitoring. Antiarrhythmic drug therapy was usually
continued until the first outpatient clinic visit at 3 months after
the ablation. If the patient was asymptomatic at the 3-month
follow-up visit and no AF was documented, then usually an-
tiarrhythmic medication was discontinued. If the patient had a
low thromboembolic risk, as assessed using the CHA2DS2-
VASc score (male < 1, female < 2), oral anticoagulation was
stopped at the 3-month follow-up visit.
2.6 Endpoints
The primary endpoints are the total dose area product (DAP);
total fluoroscopy time; and freedom from documented recur-
rence of AF lasting longer than 30 s after a single procedure
(after a blanking period of 3 months), with or without the use
of antiarrhythmic drugs. Secondary endpoints are procedure
duration, complete electrical isolation of PVs, and procedural
complications.
2.7 Statistical analysis
Continuous variables are presented as mean ± SD or median
with corresponding 25th and 75th percentile, as appropri-
ate. Categorical variables are presented by numbers and
percentages. Difference of continuous variables between
groups was analyzed with the unpaired Student t tests if
the data were normally distributed, and with the Mann–
Whitney U test otherwise. When comparing frequencies
between groups, the chi-square or Fisher’s exact test was
used, where appropriate. Cumulative freedom from AF re-
currence was constructed with the use of the Kaplan-Meier
method and groups were compared with log-rank statistics.
Furthermore, logistic regression analysis was performed
correcting for differences in baseline characteristics be-
tween groups. Data are presented as odds ratios and 95%
confidence intervals (CI). Statistical analyses were per-
formed using SPSS version 24 (IBM, Armonk, NY). All
statistical tests were two-sided. A P value < 0.05 was con-
sidered statistically significant.
Fig. 1 Example of stored
fluoroscopic image during
occlusion of the left superior
pulmonary vein demonstrating
the amount of collimation
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3 Results
3.1 Study population
A total of 90 patients underwent CB PVI within the study
period. A total of 44 patients (group B) underwent the ablation
using the modified fluoroscopy protocol starting from
June 2017. Baseline characteristics of the study population
are provided in Table 1. There was a higher proportion
of females and smaller mean LA diameter in group B
compared with group A. There were no differences in
other baseline characteristics; especially, the type of AF
was similar between both groups, with the majority of
patients having paroxysmal AF.
3.2 Primary endpoints
Procedural data are presented in Tables 2 and 3. Both the
median total DAP (1393 [827, 2842] versus 3232 [2108,
5046] cGycm2, P < 0.001) and median fluoroscopy time (19
[12, 23] versus 24 [19, 30] min, P < 0.001) were lower in
group B compared with group A. Even after correcting for
the procedure time, the median indexed DAP (157 [95, 254]
cGycm2/min versus 298 [233, 492] cGycm2/min, P < 0.001)
and median indexed fluoroscopy time (0.19 [0.14, 0.22] ver-
sus 0.21 [0.19, 0.27], P = 0.005) remained lower in group B
compared with group A.
Obesity (BMI ≥ 30 kg/m2) was associated with an almost
twofold higher radiation dose within both cohorts (group A
5348 [3267, 8630] versus 2873 [2081, 4342] cGycm2, P =
0.03; group B 2401 [1934, 8322] versus 1262 [761, 2007]
cGycm2, P = 0.003). When restricting the analysis to obese
patients (N = 20), the radiation dose was similar between both
groups (5348 [3267, 8630] versus 2401 [1934, 8322], P =
0.37, for groups A and B, respectively).
The 1-year freedom from documented AF recurrence after
a single procedure with or without antiarrhythmic drugs after a
blanking period of 3 months was 74% in group Aversus 77%
Table 1 Patient characteristics
Group A (N = 46) Group B (n = 44) P value
Age (years) 60 ± 10 57 ± 11 0.16
Female gender 7 (15%) 20 (46%) 0.002
BMI (kg/m2) 28 ± 3 27 ± 3 0.42
Obesity (BMI ≥ 30 kg/m2) 11 (24%) 9 (20%) 0.69
Hypertension 23 (50%) 16 (36%) 0.19
Diabetes mellitus 1 (2%) 2 (5%) 0.61
Prior stroke/TIA 2 (4%) 2 (5%) 1.00
CHA2DS2-VASc score 0.40
- 0 13 (28%) 14 (32%)
- 1 13 (28%) 12 (27%)
- 2 16 (35%) 13 (30%)
- 3 – 3 (7%)
- 4 4 (9%) 2 (5%)
HAS-BLED score 0.43
- 0 26 (57%) 30 (68%)
- 1 18 (39%) 12 (27%)
- 2 1 (2%) 2 (5%)
- 3 1 (2%) –
LA diameter (mm) 42 ± 5 38 ± 6 0.003
Ischemic cardiomyopathy 1 (2%) 0 (0%) 1.00
Type of AF 0.44
- Paroxysmal AF 41 (89%) 42 (96%)
- Persistent AF 4 (9%) 2 (5%)
- Long-standing persistent AF 1 (2%) 0 (0%)
Presence of common ostium 1 (2%) 3 (7%) 0.36
General anesthesia 10 (22%) 11 (25%) 0.72
Continuous data are presented as mean ± SD. Categorical data are presented as n (%)
AF atrial fibrillation, BMI body mass index, TIA transient ischemic attack
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Table 2 Ablation data
Group A (N = 46) Group B (n = 44) P value
Total number of PVs 183 173
Electrical isolation of all PVs 45 (98%) 39 (89%) 0.11
Left superior PV
- Electrical isolation 44/45 (98%) 41/41 (100%) 1.00
- Number of applications
- 1 application 35 (78%) 31 (76%) 0.81
- 180 s application 20 (44%) 17 (41%) 0.78
- 2 applications 5 (11%) 7 (17%)
- > 2 applications 5 (11%) 3 (7%)
- Minimal balloon temperature (°Celsius) − 46 (− 51, − 43) − 47 (− 51, − 44) 0.36
- Time to isolation (sec)* 55 (41, 77) 38 (32, 55) 0.13
Left inferior PV
- Electrical isolation 44/45 (98%) 39/41 (95%) 0.60
- Number of applications:
- 1 application 26 (58%) 25 (61%) 0.76
- 180 s application 16 (36%) 11 (27%) 0.38
- 2 applications 10 (22%) 10 (24%)
- > 2 applications 9 (20%) 6 (15%)
- Minimal balloon temperature (°Celsius) − 42 (− 45, − 38) − 42 (− 47, − 40) 0.34
- Time to isolation (sec)* 58 (33, 102) 86 (48, 104) 0.31
Right superior PV
- Electrical isolation 46/46 (100%) 41/44 (93%) 0.11
- Number of applications:
- 1 application 34 (74%) 32 (73%) 0.90
- 180 s application 25 (54%) 21 (48%) 0.53
- 2 applications 11 (24%) 9 (20%)
- > 2 applications 1 (2%) 3 (7%)
- Minimal balloon temperature (°Celsius) − 48 (− 54, − 44) − 52 (− 55, − 49) 0.08
- Time to isolation (sec)* 34 (28, 100) 45 (22, 60) 1.00
Right inferior PV
- Electrical isolation 45/46 (98%) 42/44 (96%) 0.61
- Number of applications:
- 1 application 34 (74%) 30 (68%) 0.55
- 180 s application 21 (46%) 14 (32%) 0.18
- 2 applications 7 (15%) 8 (18%)
- > 2 applications 5 (11%) 6 (14%)
- Minimal balloon temperature (°Celsius) − 45 (− 52, − 40) − 43 (− 48, − 39) 0.21
- Time to isolation (sec)* 45 (31, 61) 48 (37, 65) 0.66
Left common PV
- Electrical isolation 1 (100%) 2/3 (67%) 1.00
- Number of applications
- 1 application – 1 (33%) 1.00
- > 2 applications 1 (100%) 2 (66%)
- Minimal balloon temperature (°Celsius) − 34 − 40 (− 41, − 39) 1.00
Continuous data are presented as median (IQR). Categorical data are presented as n (%)
PV pulmonary vein
*When available
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in group B (P = 0.71) (Table 4, Fig. 2). The odds ratio for
freedom of AF was 1.20 (95% CI, 0.46–3.15, P = 0.71) for
group B in comparison with group A. The adjusted odds ratio
after correcting for gender and LA dimension was 1.33 (95%
CI, 0.45–3.93, P = 0.60).
When the 1-year efficacy outcome was defined using dif-
ferent accepted definitions, the clinical outcome was still sim-
ilar between groups (Table 4). Also, the 1-year rate of repeat
ablations was similar between groups: 15% in group A and
11% in group B (P = 0.59).
3.3 Secondary endpoints
The procedure duration and the proportion of patients with
complete electrical isolation were similar between groups
(Tables 2 and 3). Also, the rate of complications was similar;
3 patients in either group experienced a complication. In group
A, one patient had a femoral pseudoaneurysm and two pa-
tients a phrenic nerve palsy. In group B, two patients had a
vascular access-site bleeding and one patient suffered from a
phrenic nerve palsy and pericarditis.
4 Discussion
Using a modified fluoroscopy protocol and increased radia-
tion awareness during second-generation CB-based PVI pro-
cedures, the radiation exposure could be reduced bymore than
50% without compromising mid-term clinical outcome. The
measures used in the present study to reduce radiation expo-
sure can be easily implemented in any catheterization labora-
tory without a significant change in the approach to CB PVI.
4.1 Advantages of cryoballoon ablation
PVI is the cornerstone of AF ablation and most patients
with AF will receive only a PVI during their index abla-
tion procedure. Previous studies have shown that the clin-
ical efficacy and safety of PVI using either RF or CB
ablation is comparable [1, 2, 9], independent of the use
of contact-force catheters and the type of AF (paroxysmal
versus non-paroxysmal) [3, 10–12]. During the past de-
cade, CB ablation has emerged as an attractive single-shot
alternative to RF ablation. This widespread adoption of
CB ablation may be explained by its relative simplicity,
lack of need of 3D mapping system, shorter procedure
duration [1, 13], faster learning curve, and higher repro-
ducibility (less operator-dependent) [14]. Disadvantages
of the CB ablation are the technical challenges due to
anatomical PV variants (i.e., common ostium, supernu-
merary veins) [15], higher risk of phrenic nerve palsy
[1, 9], and higher radiation exposure [1, 4]. Radiation
exposure can lead to acute and subacute skin injury, ma-
lignancy, and genetic abnormalities. Therefore, every at-
tempt should be made to minimize radiation exposure
according to the ALARA principle.
Table 4 Efficacy outcome at






Freedom from AF, without antiarrhythmic drugs 33 (72%) 34 (77%) 0.55
Freedom from AF, with or without antiarrhythmic drugs 34 (74%) 34 (77%) 0.71
Freedom from atrial arrhythmia, without antiarrhythmic drugs 32 (70%) 33 (75%) 0.57
Freedom from atrial arrhythmia, with or without
antiarrhythmic drugs
33 (72%) 33 (75%) 0.73
Second ablation procedure 7 (15%) 5 (11%) 0.59
Categorical data are presented as n (%)
AF atrial fibrillation
Table 3 Fluoroscopy data
Group A (N = 46) Group B (n = 44) P value
Total dose area product (cGycm2) 3232 (2108, 5046) 1393 (827, 2842) < 0.001
Total effective dose (mSv) 6.5 (4.2, 10.1) 2.8 (1.7, 5.7) < 0.001
Total fluoroscopy time (min) 24 (19, 30) 19 (12, 23) < 0.001
Total dose (mGy) 194 (123, 279) 84 (55, 157) < 0.001
Procedure duration (min) 108 ± 30 99 ± 22 0.13
Continuous data are presented asmean ± SD ormedian (IQR), as appropriate. Categorical data are presented as n (%)
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4.2 Reducing radiation exposure
During a CB procedure, fluoroscopy is used for maneuvering
of catheters and sheath, assisting with the transseptal puncture,
and determining the degree of PVocclusion. Some operators
also use selective PVangiography prior to balloon inflation to
determine the PVand atrial anatomy. Various measures can be
taken to reduce radiation exposure during CB ablation proce-
dures [5]. Heightened awareness of the operator and team to
reduce radiation exposure is the first step. Technical measures
consist of lowering fluoroscopy and cine frame rates, limited
use of cine, lowering of the detector on the patient, collimation
of region of interest, and avoidance of left anterior oblique
projections [6, 7]. Non-fluoroscopic measures are the use of
ICE guidance, 3D CT overlay for PV anatomy, and real-time
pressure waveforms to assess PV occlusion [7, 16–18].
Finally, using a novel angiography platform (e.g., Philips
Azurion versus Allura system) can also reduce radiation ex-
posure but this is not easily implemented [19].
Data on fluoroscopic measures to reduce radiation expo-
sure in CB procedures and the effect on clinical outcome is
limited [6, 7]. Rubesch-Kütemeyer et al. demonstrated that
radiation exposure could be reduced by using ICE and opti-
mized settings of the X-ray system in patients with paroxys-
mal AF [7]. ICE was used for evaluation of PVocclusion, as
well as for guiding wires, mapping catheter, and the CB.
Furthermore, PV angiography was skipped prior to CB infla-
tion, fluoroscopy avoided whenever possible, frame rate re-
duced, distance between patient and detector minimized, and
collimation was optimized. The mean DAP was reduced from
4935 ± 2094 cGycm2 to 1555 ± 1219 cGycm2 (P < 0.001).
The 1-year freedom of AF was similar between groups (74%
in the optimized group versus 78%, P = 0.64) [7]. Reissmann
et al. demonstrated that by using an optimized fluoroscopy
protocol without using ICE, a lower radiation exposure (me-
dian DAP, 389 versus 2168 cGycm2, P < 0.001) could be
achieved during CB PVI in patients with paroxysmal or per-
sistent AF [6]. The optimized fluoroscopy protocol in the
latter study consisted of (1) avoidance of cine (store from
fluoroscopy), (2) reducing the fluoroscopy frame rate (from
7.5 to 3.75 pulses per second) after the transseptal puncture,
and (3) optimal collimation.
We demonstrate that by using a basic radiation reduction
strategy, we could reduce the radiation exposure by more
than 50% in comparison with the conventional approach.
Our median effective dose in the optimized fluoroscopy
group (2.8 mSv) was lower than typically encountered in
an AF ablation procedure based on the literature (16.6 mSv)
[4]. The reduction in radiation exposure remained after
correcting for the procedure duration. This implies that re-
duction in radiation exposure was due to the implemented
changes and not due to a more efficient or easier procedure
secondary to increased operator experience, technical im-
provements, or different patient population. Furthermore,
the 1-year freedom of AF was similar between groups
(77% in the modified group versus 74% in the conventional
group, P = 0.71). In contrast to the study of Rubesch-
Kütemeyer et al. [7], we only used ICE for guidance of the
transseptal puncture and not for guidance of catheters or
evaluation of PVocclusion. Our modified fluoroscopy pro-
tocol was similar to the study of Reissmann et al. [5], but our
study also provides data on mid-term outcome.
4.3 Study limitations
There are certain limitations of the study. First, the ob-
servational nature of the study may introduce bias. The
group with the modified fluoroscopy setting had a
higher proportion of females and a smaller mean LA
diameter. It is known that LA diameter is inversely cor-
related with clinical outcome after AF ablation; thus,
this may positively influence the clinical outcome of
the modified fluoroscopy group. However, even after
correcting for sex and LA diameter, there was no dif-
ference in the 1-year freedom from documented AF be-
tween groups. Second, we did not systematically collect
data on the number of PVs which showed small leaks
during balloon occlusion between groups. Thus, we can-
not comment on the differences in quality of balloon
occlusion between groups. However, we did not require
more balloon inflations in the group with the modified
fluoroscopy protocol. Finally, this was a single-center
study with a limited number of patients which may
impact the generalizability of the results.
ConclusionRadiation exposure during CB PVI can be reduced
by using a modified fluoroscopy protocol and increased radi-
ation awareness without compromising the acute and mid-
term efficacy.
Fig. 2 Freedom from AF with or without antiarrhythmic drugs stratified
by group
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